Javascript must be enabled to continue!
News about our expanded Editorial Board, Editorial Advisory Board, and other matters
View through CrossRef
Over the past 12 months, the journal has undergone some changes, and we are writing this short editorial to update our readers about these. The headlines are: (1) We have seen an increase in our journal Impact Factor in 2025 to 3.6. (2) We have experienced a strong upturn in submissions over the past two years which has generated a significant extra labour burden for our relatively small editorial board, necessitating a review of our board membership and breadth. (3) We recently advertised for new Editorial Board members, particularly seeking experts from underrepresented areas of the world, and to fill gaps in the disciplinary coverage of our existing board. We were overwhelmed with numerous applications from distinguished geography researchers. (4) We are pleased to report that five new full Editorial Board members and several further new Associate Editorial Board members have been appointed. We have also recruited a new board member who will manage our presence on social media – in particular managing a LinkedIn account for the journal. We look forward to working with these experts to further raise the profile of the journal. (5) We recognise the significant contribution made by Dr Sarah Praskievicz who stepped down from our Editorial Board at the end of 2024, and we pay tribute to her inspiring career.
Title: News about our expanded Editorial Board, Editorial Advisory Board, and other matters
Description:
Over the past 12 months, the journal has undergone some changes, and we are writing this short editorial to update our readers about these.
The headlines are: (1) We have seen an increase in our journal Impact Factor in 2025 to 3.
6.
(2) We have experienced a strong upturn in submissions over the past two years which has generated a significant extra labour burden for our relatively small editorial board, necessitating a review of our board membership and breadth.
(3) We recently advertised for new Editorial Board members, particularly seeking experts from underrepresented areas of the world, and to fill gaps in the disciplinary coverage of our existing board.
We were overwhelmed with numerous applications from distinguished geography researchers.
(4) We are pleased to report that five new full Editorial Board members and several further new Associate Editorial Board members have been appointed.
We have also recruited a new board member who will manage our presence on social media – in particular managing a LinkedIn account for the journal.
We look forward to working with these experts to further raise the profile of the journal.
(5) We recognise the significant contribution made by Dr Sarah Praskievicz who stepped down from our Editorial Board at the end of 2024, and we pay tribute to her inspiring career.
Related Results
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract
Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...
The Canberra Bubble
The Canberra Bubble
According to the ABC television program Four Corners, “Parliament House in Canberra is a hotbed of political intrigue and high tension … . It’s known as the ‘Canberra Bubble’ and i...
Financial Advisory LLM Model for Modernizing Financial Services and Innovative Solutions for Financial Literacy in India
Financial Advisory LLM Model for Modernizing Financial Services and Innovative Solutions for Financial Literacy in India
Abstract
Dynamically evolving financial conditions in India place sophisticated models of financial advisory services relative to its own peculiar conditions more in demand...

